Care | Page 265 of 309 | SpiritIndia.com

Lung Cancer :: GALES Trial of ALIMTA, pemetrexed for injection in Small Cell Lung Cancer

Eli Lilly and Company has launched a major clinical trial evaluating ALIMTA (pemetrexed for injection) in extensive-stage small cell lung cancer (SCLC), a devastating and rapidly spreading form of lung cancer. This international trial, expected to be the largest ever to be conducted in SCLC(1), will assess the potential clinical benefit of pemetrexed in combination with carboplatin, a commonly-used chemotherapeutic agent, in direct comparison to the current leading treatment option of etoposide in combination with carboplatin.

Diabetes :: FTC and FDA Act Against Internet Vendors of Fraudulent Diabetes Cures

The Federal Trade Commission (FTC) and the Food and Drug Administration (FDA), working with government agencies in Mexico and Canada, have launched a drive to stop deceptive Internet advertisements and sales of products misrepresented as cures or treatments for diabetes. The ongoing joint campaign has so far included approximately 180 warning letters and other advisories sent to online outlets in the three countries.

Pregnancy :: Medical induction of labor increases risk of amniotic-fluid embollism

A Canadian population-based cohort study has revealed that medical induction of labour increases the risk of amniotic-fluid embolism. The study was led by Dr. Michael Kramer, Canadian Institutes of Health Research (CIHR) Senior Investigator from McGill University, and will be published in the October 21st issue of The Lancet.

Renal Failure :: Homeopathy in Chronic Renal or Kidney failure (CRF)

Chronic Renal (Kidney) Failure is a fatal disease where bodily waste products (in the form of urine) collected in the body which leads to multiorgan failure. There are three procedures in modern medicine for such condition –

Health :: NIH Opens Health Information Center at Jackson Medical Mall

The National Institutes of Health opened a new health information center today at the Jackson Medical Mall in Jackson, Mississippi, affirming NIH?s commitment to providing accurate, up-to-date health information to Mississippi residents.

Health :: Racial disparities in preventive health care persist

The racial gap in preventive health care — such as Pap tests, mammograms, and prostate and colorectal cancer screenings — persists and might be larger than previously thought, a study published online in BMC Heath Services Research finds, the Washington Post reports. For the study, Kevin Fiscella, an associate professor of family medicine and community and preventive medicine at the University of Rochester’s School of Medicine, and colleagues compared self reports from patients and Medicare claims from their physicians to see when they were eligible for and last had screenings for several conditions.

Flu :: Getting a flu shot in October is a great way to ward off seasonal flu this winter.

Flu season typically lasts from December to March, but the ideal time for “high-risk” people to be inoculated with the flu vaccine is now through mid-November, says Dr. James Luby, an infectious disease expert at UT Southwestern Medical Center. Although vaccine shortages have been experienced in the past, the U.S. Centers for Disease Control and Prevention is reporting no short supplies this season.

Breast Cancer :: Mammograms reduce breast cancer deaths, but increase overdiagnosis

A new review of studies offers good news and bad news for women faced with the decision about whether to get regular mammograms. The good news is that screening mammography does reduce breast cancer mortality. The review found that women offered screening mammograms are 15 percent less likely to die of breast cancer than women who are not offered mammograms.

Asthma :: New asthma medicine – Xolair – targeting vulnerable inner-city children

UT Southwestern Medical Center is one of a handful of top research institutions evaluating a promising new medication researchers hope can reduce the severity and frequency of asthma attacks in inner-city children, a population known to have a high prevalence of severe asthma.

Heart Disease :: Ivabradine – treatment for individuals with angina, stable angina

Heart rate reduction is the cornerstone of the treatment of angina. To date, β-blockers have been the best drugs with which to achieve this. Heart rate is set by the pacemaker cells in the sinus node. Specific cardiac ion channels, f-channels, have been identified that control the rate at which these pacemaker cells initiate cardiac contraction. A selective and specific f-channel (f) current inhibitor, ivabradine, has now been developed that reduces heart rate to a degree similar to that achieved with β-blockers, but without their side effects. Ivabradine is now available for clinical use and promises to be a major and exciting treatment for individuals with angina.